Bank of New York Mellon’s Portola Pharmaceuticals, Inc. PTLA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q3 | – | Sell |
-307,215
| Closed | -$5.53M | – | 4198 |
|
|
2020
Q2 | $5.53M | Sell |
307,215
-41,595
| -12% | -$579K | ﹤0.01% | 2161 |
|
|
2020
Q1 | $2.49M | Buy |
348,810
+36,561
| +12% | +$456K | ﹤0.01% | 2446 |
|
|
2019
Q4 | $7.46M | Buy |
312,249
+3,708
| +1% | +$102K | ﹤0.01% | 2140 |
|
|
2019
Q3 | $8.28M | Buy |
308,541
+30,650
| +11% | +$860K | ﹤0.01% | 2023 |
|
|
2019
Q2 | $7.54M | Sell |
277,891
-8,839
| -3% | -$277K | ﹤0.01% | 2124 |
|
|
2019
Q1 | $9.95M | Sell |
286,730
-1,284
| -0.4% | -$37K | ﹤0.01% | 1975 |
|
|
2018
Q4 | $5.62M | Sell |
288,014
-86,205
| -23% | -$1.77M | ﹤0.01% | 2212 |
|
|
2018
Q3 | $9.96M | Sell |
374,219
-21,944
| -6% | -$716K | ﹤0.01% | 2029 |
|
|
2018
Q2 | $15M | Sell |
396,163
-1,369
| -0.3% | -$52.4K | ﹤0.01% | 1778 |
|
|
2018
Q1 | $13M | Buy |
397,532
+19,526
| +5% | +$857K | ﹤0.01% | 1849 |
|
|
2017
Q4 | $18.4M | Buy |
378,006
+43,979
| +13% | +$2.22M | ﹤0.01% | 1614 |
|
|
2017
Q3 | $18M | Buy |
334,027
+56,385
| +20% | +$3.31M | 0.01% | 1627 |
|
|
2017
Q2 | $15.6M | Buy |
277,642
+26,919
| +11% | +$1.08M | ﹤0.01% | 1706 |
|
|
2017
Q1 | $9.82M | Buy |
250,723
+18,211
| +8% | +$580K | ﹤0.01% | 1978 |
|
|
2016
Q4 | $5.22M | Buy |
232,512
+9,609
| +4% | +$188K | ﹤0.01% | 2290 |
|
|
2016
Q3 | $5.06M | Sell |
222,903
-30,738
| -12% | -$721K | ﹤0.01% | 2235 |
|
|
2016
Q2 | $5.99M | Buy |
253,641
+3,692
| +1% | +$91.2K | ﹤0.01% | 2120 |
|
|
2016
Q1 | $5.1M | Sell |
249,949
-45,367
| -15% | -$1.44M | ﹤0.01% | 2174 |
|
|
2015
Q4 | $15.2M | Buy |
295,316
+29,675
| +11% | +$1.44M | ﹤0.01% | 1579 |
|
|
2015
Q3 | $11.3M | Buy |
265,641
+1,368
| +0.5% | +$66K | ﹤0.01% | 1791 |
|
|
2015
Q2 | $12M | Buy |
264,273
+13,955
| +6% | +$561K | ﹤0.01% | 1856 |
|
|
2015
Q1 | $9.5M | Buy |
250,318
+26,523
| +12% | +$911K | ﹤0.01% | 1980 |
|
|
2014
Q4 | $6.34M | Sell |
223,795
-6,027
| -3% | -$168K | ﹤0.01% | 2178 |
|
|
2014
Q3 | $5.81M | Buy |
229,822
+42,393
| +23% | +$1.12M | ﹤0.01% | 2219 |
|
|
2014
Q2 | $5.47M | Buy |
187,429
+84,768
| +83% | +$2.05M | ﹤0.01% | 2283 |
|
|
2014
Q1 | $2.66M | Buy |
102,661
+3,538
| +4% | +$94.4K | ﹤0.01% | 2700 |
|
|
2013
Q4 | $2.55M | Buy |
99,123
+57,116
| +136% | +$1.39M | ﹤0.01% | 2736 |
|
|
2013
Q3 | $1.12M | Sell |
42,007
-5,449
| -11% | -$130K | ﹤0.01% | 3173 |
|
|
2013
Q2 | $1.17M | Buy |
+47,456
| New | +$943K | ﹤0.01% | 3103 |
|
Bank of New York Mellon's PTLA Position: Q3 2020 in Review
Bank of New York Mellon sold out of Portola Pharmaceuticals, Inc. (PTLA) in Q3 2020, closing a stake of 307,215 shares — an estimated $5.53M sold.
Bank of New York Mellon first reported a position in PTLA in Q2 2013 and held it in 29 quarters. The position peaked at $18.4M in Q4 2017. 0 funds tracked by Wall St. Rank hold PTLA as of Q3 2020.
- Bank of New York Mellon reported no remaining Portola Pharmaceuticals, Inc. position as of Q3 2020 after selling out during the quarter.
- Bank of New York Mellon sold 307,215 Portola Pharmaceuticals, Inc. shares in Q3 2020, an estimated $5.53M.
- Bank of New York Mellon first reported a position in Portola Pharmaceuticals, Inc. in Q2 2013 and held it in 29 quarters.
- Bank of New York Mellon's Portola Pharmaceuticals, Inc. position peaked at $18.4M in Q4 2017.
- 0 funds tracked by Wall St. Rank held Portola Pharmaceuticals, Inc. as of Q3 2020.
Based on Bank of New York Mellon's 13F filing for Q3 2020, filed 12 Nov 2020.